Ideal Particle Sizes for Inhaled Steroids Targeting Vocal Granulomas: Preliminary Study Using Computational Fluid Dynamics

Elizabeth L. Perkins, MD1, Saikat Basu, PhD1, Guilherme J. M. Garcia, PhD2,3, Robert A. Buckmire, MD1, Rupali N. Shah, MD1, and Julia S. Kimbell, PhD1

Abstract

Objectives. Vocal fold granulomas are benign lesions of the larynx commonly caused by gastroesophageal reflux, intubation, and phonotrauma. Current medical therapy includes inhaled corticosteroids to target inflammation that leads to granuloma formation. Particle sizes of commonly prescribed inhalers range over 1 to 4 μm. The study objective was to use computational fluid dynamics to investigate deposition patterns over a range of particle sizes of inhaled corticosteroids targeting the larynx and vocal fold granulomas.

Study Design. Retrospective, case-specific computational study.

Setting. Tertiary academic center.

Subjects/Methods. A 3-dimensional anatomically realistic computational model of a normal adult airway from mouth to trachea was constructed from 3 computed tomography scans. Virtual granulomas of varying sizes and positions along the vocal fold were incorporated into the base model. Assuming steady-state, inspiratory, turbulent airflow at 30 L/min, computational fluid dynamics was used to simulate respiratory transport and deposition of inhaled corticosteroid particles ranging over 1 to 20 μm.

Results. Laryngeal deposition in the base model peaked for particle sizes 8 to 10 μm (2.8%-3.5%). Ideal sizes ranged over 6 to 10, 7 to 13, and 7 to 14 μm for small, medium, and large granuloma sizes, respectively. Glottic deposition was maximal at 10.8% for 9-μm-sized particles for the large posterior granuloma, 3 times the normal model (3.5%).

Conclusion. As the virtual granuloma size increased and the location became more posterior, glottic deposition and ideal particle size generally increased. This preliminary study suggests that inhalers with larger particle sizes, such as fluticasone propionate dry-powder inhaler, may improve laryngeal drug deposition. Most commercially available inhalers have smaller particles than suggested here.

Keywords

computational fluid dynamics (CFD), inhaled corticosteroids, vocal fold granuloma

Vocal fold granulomas are benign epithelial lesions and were first reported in 1928 by Chevalier Jackson as “contact ulcers of the larynx.” Generally accepted etiologies include phonotrauma, gastroesophageal reflux (GERD), intubation, and surgical trauma. Various treatments for vocal fold granulomas include gastric acid suppression, speech therapy, intralesional or inhaled steroid therapy, botulinum toxin injections, or some combination of the aforementioned.3-6 Recent use of the in-office potassium titanyl phosphate (KTP) laser has also been described.7 Surgical excision is typically reserved for patients who fail medical therapy, present with large symptomatic granulomas, or have acute airway obstruction.3,7

Vocal fold granulomas can be difficult to treat given their remote location and propensity to recur, particularly following surgical excision. Inhaled corticosteroids are a noninvasive topical approach to target the reactive, inflammatory process behind granuloma formation.8 The use of
inhaled corticosteroids to treat vocal fold granulomas was first introduced in the literature by Roh and colleagues in 1999. They reported that the use of inhaled budesonide resulted in 95% resolution of intubation-induced granulomas. This was followed by Hillel et al in 2010, who reported a complete response in 69% of patients treated with the concurrent use of a proton pump inhibitor and inhaled triamcinolone.

The most commonly prescribed inhaled corticosteroids include fluticasone propionate dry-powder inhaler (DPI) (Advair DISKUS; GlaxoSmithKline, Research Triangle Park, North Carolina); budesonide formeterol fumarate dihydrate hydrofluoroalkane (HFA) (Symbicort; AstraZeneca, London, England); mometasone furoate DPI (Asmanex, Merck Sharp & Dohme Corp, Kenilworth, New Jersey); fluticasone propionate HFA (Flovent; GlaxoSmithKline); QVAR (TEVA Pharmaceuticals, North Wales, Pennsylvania); Alvesco (SUNovion Pharmaceuticals, Marlborough, Massachusetts).

### Table 1. Inhaled Corticosteroid Particle Sizes

<table>
<thead>
<tr>
<th>Inhaled Corticosteroid</th>
<th>Particle Size MMAD (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclesonide HFA (Alvesco)</td>
<td>1.0</td>
</tr>
<tr>
<td>Beclomethasone dipropionate HFA (QVAR)</td>
<td>1.1</td>
</tr>
<tr>
<td>Fluticasone propionate HFA (Flovent HFA)</td>
<td>2.4</td>
</tr>
<tr>
<td>Mometasone furoate DPI (Asmanex)</td>
<td>3.7</td>
</tr>
<tr>
<td>Budesonide formeterol fumarate dihydrate HFA (Symbicort)</td>
<td>3.7</td>
</tr>
<tr>
<td>Fluticasone propionate DPI (Advair DISKUS)</td>
<td>4.0</td>
</tr>
</tbody>
</table>

Abbreviations: DPI, dry-powder inhaler; HFA, hydrofluoroalkane; MMAD, Mass Median Aerodynamic Diameter.

Products and manufacturers are the following: Advair (GlaxoSmithKline, Research Triangle Park, North Carolina); Symbicort (AstraZeneca, London, England); Asmanex (Merck Sharp & Dohme Corp, Kenilworth, New Jersey); Flovent (GlaxoSmithKline); QVAR (TEVA Pharmaceuticals, North Wales, Pennsylvania); Alvesco (SUNovion Pharmaceuticals, Marlborough, Massachusetts).

In the current work, we employed CFD tracking to simulate and quantify inhaled particle deposition on the larynx for a wide range of particle sizes (1-20 µm), including those commercially available (1-4 µm). In addition, we aimed to investigate particle size ranges that may potentially result in maximal glottic deposition in the setting of vocal fold granulomas and how topical deposition may be affected by granuloma sizes and position.

### Materials and Methods

#### 3D Model Creation

This study used existing, de-identified patient data and was approved with exempt status by the institutional review board (IRB) at the University of North Carolina at Chapel Hill. Computed tomography (CT) scans from 2 male subjects, 56 and 67 years old, respectively, were retrospectively selected, de-identified, and combined to generate a 3-dimensional (3D) reconstruction of a normal adult airway. The first study subject had subglottic stenosis and 2 CT scans of the neck, one with ideal mouth opening for virtual placement of an inhaler and one with ideal vocal fold positioning for inhalation. The CT scans were imported and edited in Mimics 18.0 (Materialize, Plymouth, Michigan). The 2 models from the first study subject were seamlessly joined without any alterations in airway diameter. To avoid confounding effects from subglottic stenosis, this reconstruction was joined with an upper tracheal reconstruction from a CT scan of the second study subject with a healthy subglottis and trachea. To match cross-sectional area at the mid-subglottal joining region, the healthy upper tracheal reconstruction was scaled by 70% and 85% in the left-to-right and anterior-to-posterior directions, respectively. The final, hybrid model ensured a reasonable representation of a normal airway.

A CT-based reconstruction of an HFA inhaler was virtually fitted into the open mouth of the 3D airway, which was then exported in stereolithography (STL) format and imported into ICEM-CFD 15.0 (ANSYS, Canonsburg, Pennsylvania), a computer-aided design and meshing software. Using ICEM-CFD, a glottic deposition area was designated, including the glottis and a small portion of the distal supraglottis, based on anatomic landmarks identified on the CT scans (Figure 1).

Through the design tools in ICEM-CFD, virtual granulomas were constructed as semi-spherical protrusions incorporated into the vocal fold area of the normal laryngeal model. Three different granuloma sizes were created: small, medium, and large, with diameters of 3, 4, and 6.5 mm, respectively. We chose the large granuloma to represent 50% of length of the vocal fold of our model, with medium and small granulomas equivalent to 30% and 20% of vocal fold length, respectively.

The granulomas were positioned at 3 different locations along the length of the membranous vocal fold: the anterior...
commissure, the mid-vocal fold, and the posterior vocal fold (Figure 2). We chose to investigate granulomas at different lengths along the vocal fold to determine if inhaled corticosteroids have preferential deposition locations there, since such findings would have potential therapeutic and preventative applications. Nine models were constructed and used for further analysis, including the normal “base” model. Note that we omitted a model with the large anterior commissure granuloma, owing to its unrealistic size and the resultant anatomic nonviability for such a growth at that location.

For each of the models, using protocols based on mesh refinement studies, a computational grid of 6 million unstructured tetrahedral elements filling the inhaler-airway reconstruction was created in ICEM-CFD, with 4 layers of 0.1-mm graded prism cells at the airway-tissue interfaces. Mesh quality was found sufficient for reliable numerical performance.

Flow and Particle Transport Simulations

Steady-state inspiratory airflow was simulated using the CFD software package Fluent (ANSYS, Canonsburg, Pennsylvania). The airflow rate was set at 30 L/min under pressure-driven conditions, with air entering through the nose and the inhaler. Particles with a density of 1 g/cm³ and aerodynamic diameters ranging from 1 to 20 µm were released passively from 25,679 locations spread evenly over a planar cross section at the inhaler outlet and tracked using Fluent’s Discrete Phase Model (DPM). Results were not sensitive to increasing numbers of release locations (details to follow in the Results section).

Reynolds number ($Re$) is a critical marker of the airflow. A ratio of the convective inertia of the flow to its viscosity, it is calculated as $Re = \frac{\rho \cdot v \cdot D_h}{\mu}$, where $\rho$ is the inspired air density (1.204 kg/m³), $v$ is the flow velocity at a cross section, $D_h$ is the cross-sectional hydraulic diameter, and $\mu$ is the dynamic viscosity of air ($1.825 \times 10^{-5}$ kg/m·s). $Re$ of 1900 to 3100 have been observed for time-variable glottal motion during human breathing. Airflow through a pipe, which is a simplistic idealization for tracheal flow, develops turbulence beyond $Re \approx 2700$. The average $Re$ for the 9 current models (≈ 3740) exceeded these thresholds and ranged from 3429 to 4348, suggesting sustained turbulence in inspiratory airflow.

Feasibility of the 3D meshes to run turbulence modeling schemes was checked using $y^+$, a model-specific parameter that detects turbulence possibility close to the wall and ascertains if the mesh is fine enough to resolve such flow scales. It is computed as $y^+ = (\Delta / v)\sqrt{\tau_w / \rho}$, where $\tau_w$ is the wall shear stress, $\Delta$ is the normal distance from the wall to the mesh element center, and $v$ is the kinematic viscosity of air. Smaller values ($y^+ < 5$) imply laminar sublayers in near-wall regions, while $y^+ > 30$ suggests fully turbulent layers. In our simulations, $y^+$ averaged 4.35 and confirmed mesh adequacy for implementing the shear-stress transport based $k-\omega$ model with low $Re$ corrections, using Reynolds-averaged Navier Stokes (RANS) equations. Similar modeling frameworks have been shown to agree with in vivo data for monodisperse aerosol deposition in mouth-throat models.

In this study, the CFD-based inhaled particle transport findings were reported as the percentage of the number of

Figure 1. (A) Side view of airway model. (B) Enlarged view of glottic deposition, dark line at the level of the vocal folds. (C) Cross section of the computational mesh at the vocal folds. (D) Outline of vocal fold cross section used for computing hydraulic diameter.
particles released of each size (25,679) that deposited in the glottic deposition area (Figure 1). Based on the numerical results, the “ideal” particle size was computationally determined for the individual granuloma types. This was reported as a range (eg, 6-10 μm) by dividing the maximum deposition fraction among the 20 particle sizes for each granuloma case into quartiles and including all sizes whose deposition fraction fell within the top quartile (assumed to be within 25% of the maximum deposition fraction).

Results
In the normal or “base” model, larger particles (16-20 μm) were predicted to deposit in the mouth, oropharynx, and proximal supraglottis, while smaller particle sizes (1-15 μm) were more dispersed throughout the airway (Figure 3) or escaped into the trachea and lungs. A maximum glottic deposition of 3.5% was predicted at 9 μm, and a minimum deposition of 0.3% was predicted at the 18-μm particle size (Figure 4).

The granuloma models revealed greater glottic deposition than the base model at all sizes and positions for all particle sizes except 1 μm, with the exception of the small anterior commissure granuloma. The small anterior granuloma had a minimal effect on glottic deposition, with a maximal deposition of 3.49% at 7 μm compared to 3.50% at 9 μm for the normal model (Figure 5). The large, posterior granuloma had the greatest percentage of glottic deposition of 10.8% at 9 μm, 3 times that of the normal model (3.5%). The small anterior granuloma had the lowest particle deposition (0.02%) at 18 μm. Within each granuloma size (small, medium, large), the more posteriorly located granulomas had the largest glottic deposition, and the anterior granulomas had the smallest particle deposition (Figure 5).

The range of particle sizes that targeted the simulated normal glottis most effectively was 8 to 10 μm (2.8%-3.5%). Ideal particle size was influenced by the presence of a granuloma. As the granulomas grew in size and their locations moved posteriorly along the vocal fold, the ideal

![Figure 2. Top view of glottic area showing the placement of spheres along the vocal folds to represent 3 granuloma sizes and locations.](image-url)
particle size to target the larynx generally increased (Figure 6). In addition, the span of the particle size range also tended to increase. The large, posterior granuloma had a wider range of ideal sizes (7-14 μm), compared to 8 to 10 μm for the normal model and 6 to 10 μm for the small, anterior granuloma (see Figure 7).

Within the particle size range of the commercially available inhaled corticosteroids (1-4 μm), glottic deposition was largest for the 4-μm particle size among all granuloma cases. The large posterior granuloma had the largest glottic deposition of the 4-μm particle size (3.13% vs 1.69% for the base model).

To address potential variability between multiple particle simulations, we performed a sensitivity analysis by varying the total number of particles released from the inhaler outlet. This entailed changing the number of release locations on the inhaler outlet. For 3 representative particle sizes (2, 4, and 8 μm), simulations were run using approximately 5000, 10,000, 25,000, 50,000, and 100,000 release locations. The statistical variability in deposition was miniscule. Standard deviations of the percentage of the total number of inhaled particles deposited on the supraglottis, glottis, and granuloma ranged between 0.016% and 0.75% for 2-μm particles, 0.011% and 0.083% for 4-μm particles, and 0.023% and 0.287% for 8-μm particles. An anatomy-based investigation of the statistical variability would require consideration of multiple study subjects, which was beyond the scope of the current work.

Discussion

The introduction of inhaled corticosteroids in the treatment of granulomas provides a safe and effective therapeutic option with minimal side effects. Inhaled corticosteroids were designed to treat disease of the terminal bronchi and lungs, such as chronic obstructive pulmonary disease and asthma. In such a setting, laryngeal deposition can be an unwanted side effect and lead to steroid-induced laryngitis. In treating vocal fold granulomas, the goal is the opposite, to specifically target the granuloma and glottis. Our study was designed to initiate investigation of the following clinical question: which inhaled corticosteroid would be ideal to target the larynx and how may this be affected by the presence of a granuloma?

While preliminary, the results presented here provide an interesting first look at the possibility that certain particle sizes may preferentially target the vocal folds and granulomas. The available prescribed inhaled corticosteroids have particles sizes ranging over 1 to 4 μm and are smaller than the particle size that best targeted the glottis in our study. While all particle sizes have some proportion of laryngeal deposition, small particle size is ideal for traversing the larynx to target the terminal bronchi, which has been the goal of the commercially available inhaled corticosteroids. In our computational model, within the 1- to 4-μm range, the 4-μm size had the largest glottic deposition among all our simulated granuloma cases, suggesting that an inhaler with a larger particle size may improve targeting the larynx (ie, fluticasone propionate DPI Advair DISKUS). This may also help explain the clinical observation that this product anecdotally produces more frequent steroid-induced laryngitis than other preparations.

In our model, particles that targeted the glottis constituted a range of much larger inhaled particle sizes (8-10 μm) than those commercially available. Presence of a granuloma (specifically, larger and more posteriorly located granuloma) appeared to increase glottic deposition of inhaled particles. In addition, the larger granulomas had a wider range of predicted ideal particle size (7-14 vs 8-10 μm), which suggests that prescribing an inhaled corticosteroid for a larger granuloma could be less preferential.
The development of our model necessitated a series of assumptions. During model construction, we assumed that the virtual placement of the inhaler in the model was an adequate approximation of an actual position according to usage instructions and that our semi-spherical granuloma constructions approximated actual granuloma profiles protruding into the airspace at the vocal fold. We also assumed that our model approximated vocal fold position during inhaler use. The exact position of the vocal folds during inhaler use may be variable but was assumed to be in an inhaled, slightly abducted position in our model.

Inspiration and expiration clearly have acceleratory and deceleratory components. However, as a simplistic assumption, the steady-state condition can be considered a reliable approximation for the brief single-cycle inspiratory span over which the inhaled particles are tracked in our numerical models. Our preliminary work and other existing findings on time-dependent simulations of sinonasal flows lend support to the assumption of a steady-state airflow framework for resting breathing.

The current study has limited clinical application at this stage, as it did not account for individual variations in anatomy, inhalation rates, and airflow, which subsequently may lead to interindividual fluctuations in the airflow. By passively releasing the particles from the outlet of the inhaler,
we assumed that particle velocity owing to the inhaler ejection forces had diminished to zero once the particles reached the outlet, and we further assumed that the particles did not interact with each other, affect inspiratory airflow, or reenter the airspace after touching an airway wall. Comparison of our results with models constructed from imaging of actual vocal fold granulomas clinically confirmed vocal fold position during inhaler use, and extension to other individuals and airflow rates are needed for assessment of these effects.

Our simulations represent a computational model of the human airway. The airway is dynamic, and although CFD studies using conventional CT-based geometries have been proven to be effective and accurate for predicting airflow and transport, these methods produce static simulations.37,38 Miyawaki et al39 demonstrated a 7% difference of particle deposition between static vs dynamic CFD analysis of the adult human airway. Despite the relatively small variance, the translation of this difference to our model and the clinical setting is yet to be determined.

Conclusions
This pilot study used CFD techniques to predict the ideal inhaled particle size range for targeted laryngeal deposition in the setting of vocal fold granulomas in 1 subject. The numerical simulations suggested that in general, the presence of a granuloma facilitated localized glottic deposition of the inhaled particles. As the size of the granuloma increased, and with an increasingly posterior location along the vocal fold, glottic deposition and the ideal particle size for targeted delivery generally increased. The most commonly prescribed inhalers release particle sizes (1-4 \( \mu m \)) that are smaller than our model-based predictions on the “ideal” sizes to target the glottis (8-10 \( \mu m \)). The findings, while preliminary, are compelling and warrant further investigations. These include validating our CFD numerical results in an in vitro 3D printed laryngeal model and accounting for the dynamic nature of the human airway with in vivo studies. Eventually, this line of research may lead to the development of novel inhalers designed to produce particles customized for therapeutic laryngeal delivery.

Acknowledgments
The authors gratefully acknowledge the technical assistance of Nichole Witten.

Author Contributions
Elizabeth L. Perkins, design, data acquisition, and analysis; primary author; final approval of the content; agreement to be accountable for the work; Saikat Basu, design, data acquisition, and analysis; critical revisions and drafting; final approval of the content; agreement to be accountable for the work; Guilherme J. M. Garcia, concept and design, critical revisions, final approval of the content, agreement to be accountable for the work; Robert A. Buckmire, design and interpretation of data, critical revisions, final approval of the content, agreement to be accountable for the work; Rupali N. Shah, design and interpretation of data, critical revisions, final approval of the content, agreement to be accountable for the work; Julia S. Kimbell, design, data acquisition, and analysis; critical revisions; final approval of the content; agreement to be accountable for the work.
Disclosures

Competing interests: Rupali N. Shah has consulted for Bryan Medical, which has no product involved in the study; Julia S. Kimbell receives partial salary support and funds for supplies and travel from Applied Research Associates for a separate, unrelated project.

Sponsorships: None.

Funding source: Research reported in this publication was supported in part by the National Heart, Lung and Blood Institute of the National Institutes of Health under award number R01HL122154. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References


